vitiligo
Conditions
Interventions
test group:NB-UVB + lipoic acid tablets + compound betamethasone injection
control group:NB-UVB + placebo + compound betamethasone injection
Sponsors
The First Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
14 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) age 14-65 years old, inpatient or outpatient, male or female; (2) meet the diagnostic criteria of clinically diagnosed advanced primary sporadic vitiligo patients; (3) subjects volunteered to participate, be required to sign an informed consent form; (4) leukoplakia dispersed in the three anatomical district, there is at least one greater than 2cm, with a total area of> 1% of body surface area.
Exclusion criteria
Exclusion criteria: (1) pregnant and lactating women; (2) serious heart, liver, renal insufficiency; (3) pre-cancerous skin lesions; (4), systemic lupus erythematosus (SLE), dermatomyositis ultraviolet treatment contraindications; (5) diabetes; (6) with immunosuppressive therapy; Nearly 2 months; (7) received glucocorticoid NB-UVB excimer laser treatment, nearly one month to accept any treatment, at the same time to participate in other clinical trials; (8) secondary vitiligo (such as secondary to discoid lupus erythematosus, chronic eczema, vitiligo); (9) can not adhere to treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| lesion change; | — |
Countries
China
Contacts
Public ContactXing-hua Gao
Outcome results
None listed